J Korean Med Sci.  2020 Sep;35(36):e328. 10.3346/jkms.2020.35.e328.

Clinical Characteristics and Mortality Predictors of COVID-19 Patients Hospitalized at Nationally-Designated Treatment Hospitals

Affiliations
  • 1Department of Internal Medicine, Dongguk University College of Medicine, Gyeongju, Korea
  • 2Department of Preventive Medicine, Dongguk University College of Medicine, Gyeongju, Korea
  • 3Department of Internal Medicine, Andong Medical Center, Andong, Korea
  • 4Department of General Surgery, Andong Medical Center, Andong, Korea
  • 5Department of Pediatrics, Dongguk University College of Medicine, Gyeongju, Korea

Abstract

Background
Coronavirus disease 2019 (COVID-19) was first reported in December 2019 in China, and then it has disseminated worldwide. In Korea, a religious group-related super-spreading event triggered a sudden outbreak in Daegu city and Gyeongsangbuk-do in southeast Korea. This study was undertaken to document the clinical characteristics of patients hospitalized in Gyeongsangbuk-do.
Methods
Three hundred and fifty-two patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection hospitalized at Dongguk University Gyeongju Hospital or at the Andong Medical Center between February 18th and June 30th were enrolled in this study. Medical records were reviewed and demographic and clinical features, including comorbidities, symptoms, radiological and laboratory findings on admission were analyzed. In addition, we sought to identify risk factors of mortality.
Results
Mean age of the 352 study subjects was 56 years (range, 14–95). The mortality rate was 6.8% and mean age at death was 81 years (range, 57–91). The most common symptom was cough (31.8%) followed by a febrile sensation (28.4%), sputum (17.0%), sore throat (15.6%), and myalgia (13.1%). Eighty-one (23.0%) patients were asymptomatic, but a half of these patients exhibited pneumonic infiltration at presentation. Chest radiology showed no active lesion in 41.8% of the study subjects, bilateral pneumonia in 46.9%, and unilateral pneumonic infiltration in 11.4%. Among 24 patients that died, 18 subjects were transferred from a care facility. An age of ≥ 70 years, previous history of malignancy or diabetes, and fever (≥ 37.5°C) on admission were found to be significant risk factors of mortality.
Conclusion
Patients aged ≥ 70 years, those with fever on admission, and patients with an underlying malignancy or diabetes were found to be more likely to succumb to COVID-19. Elderly in care facilities or hospitalized patients with an underlying disease should receive more attention and be considered for preventive quarantine.

Keyword

Coronavirus; Mortality; Pandemics; Hospitals; Korea

Cited by  5 articles

Oral cavity cancer management during the COVID-19 pandemic
Joo Yong Park
J Korean Assoc Oral Maxillofac Surg. 2020;46(6):371-372.    doi: 10.5125/jkaoms.2020.46.6.371.

Clinical Features of COVID-19 in Uzbekistan
KyungHee Kim, Jae Wook Choi, Juyoung Moon, Habibulla Akilov, Laziz Tuychiev, Bakhodir Rakhimov, Kwang Sung Min
J Korean Med Sci. 2020;35(45):e404.    doi: 10.3346/jkms.2020.35.e404.

Clinical Characteristics and Outcomes of COVID-19 Cohort Patients in Daegu Metropolitan City Outbreak in 2020
Shin-Woo Kim, Seung-Mee Kim, Yu Kyung Kim, Jong-yeon Kim, Yu-Mi Lee, Bong-Ok Kim, Suhyun Hwangbo, Taesung Park
J Korean Med Sci. 2020;36(1):e12.    doi: 10.3346/jkms.2021.36.e12.

Clinical Characteristics of COVID-19: Risk Factors for Early Oxygen Requirement after Hospitalization
Hyeon Jeong Suh, Eunyoung Lee, Sang-Won Park
J Korean Med Sci. 2021;36(19):e139.    doi: 10.3346/jkms.2021.36.e139.

Risk Factors of Outcomes of COVID-19 Patients in Korea: Focus on Early Symptoms
Su Yeon Jang, Jeong-Yeon Seon, Baik-Lin Eun, Seong-Beom Koh, Jin-Hong Yoo, Woo Yong Lee, Ho-Kee Yum, Seok-Jun Yoon, In-Hwan Oh, Sang-Cheol Bae, Sung-Goo Chang
J Korean Med Sci. 2021;36(18):e132.    doi: 10.3346/jkms.2021.36.e132.


Reference

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727–733. PMID: 31978945.
Article
2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382(13):1199–1207. PMID: 31995857.
3. World Health Organization. Updated 2020. Accessed July 19, 2020. https://covid19.who.int.
4. World Health Organization. Statement on the second meeting of the international health regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV). Update 2020. Accessed July 19, 2020. https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).
5. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19(5):305–306. PMID: 32273591.
Article
6. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020; 30(3):313–324. PMID: 32238757.
Article
7. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020; 38(1):1–9. PMID: 32105090.
Article
8. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020; 35(6):e79. PMID: 32056407.
Article
9. Kim ES, Chin BS, Kang CH, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci. 2020; 35(13):e142. PMID: 32242348.
Article
10. Korea Center of Disease Control and Prevention. COVID-19 response: Korean government's response system (as of February 25, 2020). Update 2020. Accessed July 19, 2020. http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=111&dataGubun=&ncvContSeq=&contSeq=&board_id=.
11. Kim SW, Lee KS, Kim K, Lee JJ, Kim JY. Daegu Medical Association. A brief telephone severity scoring system and therapeutic living centers solved acute hospital-bed shortage during the COVID-19 outbreak in Daegu, Korea. J Korean Med Sci. 2020; 35(15):e152. PMID: 32301298.
Article
12. Korea Center of Disease Control and Prevention. Coronavirus disease-2019, Republic of Korea. Update 2020. Accessed July 19, 2020. http://ncov.mohw.go.kr/en/.
13. Korea Center of Disease Control and Prevention. Global locations with COVID-19. Update 2020. Accessed July 19, 2020. http://ncov.mohw.go.kr/en/bdBoardList.do?brdId=16&brdGubun=163&dataGubun=&ncvContSeq=&contSeq=&board_id=.
14. Korea Center of Disease Control and Prevention. Cases in Korea. Update 2020. Accessed August 24, 2020. http://ncov.mohw.go.kr/bdBoardList_Real.do?brdId=1&brdGubun=11&ncvContSeq=&contSeq=&board_id=&gubun=.
15. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA. 2020; 323(15):1502–1503. PMID: 32105304.
Article
16. Chen M, An W, Xia F, Yang P, Li K, Zhou Q, et al. Clinical characteristics of rehospitalized patients with COVID-19 in China. J Med Virol. Forthcoming. 2020; DOI: 10.1002/jmv.26002.
Article
17. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020; 35(5):e61. PMID: 32030925.
Article
18. Obukhov AG, Stevens BR, Prasad R, Li Calzi S, Boulton ME, Raizada MK, et al. SARS-CoV-2 infections and ACE2: clinical outcomes linked with increased morbidity and mortality in individuals with diabetes. Diabetes. 2020; 69(9):1875–1886. PMID: 32669391.
Article
19. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; 57:279–283. PMID: 32173110.
Article
20. El-Lababidi RM, Mooty M, Bonilla MF, Salem NM. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a. IDCases. 2020; 21:e00837. PMID: 32483527.
Article
21. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020; 44:e40. PMID: 32256547.
Article
22. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55(5):2000524. PMID: 32269088.
Article
23. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46(5):846–848. PMID: 32125452.
Article
24. Sun Y, Koh V, Marimuthu K, Ng OT, Young B, Vasoo S, et al. Epidemiological and clinical predictors of COVID-19. Clin Infect Dis. 2020; 71(15):786–792. PMID: 32211755.
25. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; 31:e3319.
26. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care. 2020; 8(1):e001343.
Article
27. Chung SM, Lee YY, Ha E, Yoon JS, Won KC, Lee HW, et al. The risk of diabetes on clinical outcomes in patients with coronavirus disease 2019: a retrospective cohort study. Diabetes Metab J. 2020; 44(3):405–413. PMID: 32602272.
Article
28. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19): China, 2020. China CDC Wkly. 2020; 2(8):113–122.
29. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020; 31(6):1068–1077.e3. PMID: 32369736.
Article
30. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract. 2020; 162:108142. PMID: 32278764.
Article
31. Noh J, Chang HH, Jeong IK, Yoon KH. Coronavirus disease 2019 and diabetes: the epidemic and the Korean Diabetes Association perspective. Diabetes Metab J. 2020; 44(3):372–381. PMID: 32613777.
Article
32. Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020; 18(4):366–369.
Article
33. Dariya B, Nagaraju GP. Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. Cytokine Growth Factor Rev. 2020; 53(53):43–52. PMID: 32409230.
Article
34. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020; 323(18):1775–1776. PMID: 32203977.
Article
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr